The role of High-mobility group box-1 and Psoriasin in multiple myeloma: Analysis of a population affected by monoclonal gammopathies and review of the literature

• Published in: Pathology, research and practice research and practice, 2023-07, Vol.247, p.154562-154562, Article 154562
• Main Authors: Casciaro, Marco, Vincelli, Donatella, Ferraro, Maria, Mirabile, Giuseppe, Pace, Elisabetta, Martino, Bruno, Tonacci, Alessandro, Gangemi, Sebastiano, Pioggia, Giovanni, Allegra, Alessandro
• Format: Article
• Language: English
• Subjects: Alarmins; High-mobility group box-1; HMGB1 Protein; Humans; Inflammation; Monoclonal gammopathies of uncertain significance; Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Paraproteinemias; Psoriasin; RAGE; S100 Calcium Binding Protein A7; Tumorigenesis
• ISSN: 0344-0338; 1618-0631
• DOI: 10.1016/j.prp.2023.154562

Multiple myeloma (MM) is a plasma cells neoplasm which is often preceded by a preneoplastic condition called monoclonal gammopathy of unknown significance (MGUS). A protein called High-mobility group box-1 (HMGB-1) controls transcription and genomic stability. Both pro- and anti-tumor properties of HMGB1 have been described during tumor growth. The S100 protein family includes a protein known as psoriasin. Poorer prognosis and survival were linked to higher psoriasin expression in cancer patients. The goal of the current investigation was to compare the plasma levels of HMGB-1 and psoriasin in patients with MM and MGUS significance, as well as in a group of healthy controls. According to our research, patients with MGUS have higher HMGHB-1 concentrations than healthy controls (846.7 ± 287.6 pg/ml vs. 176.9 ± 204.8 pg/ml for controls, p